Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
ConclusionModel results suggest that adding canagliflozin 100 mg to SoC can improve patient outcomes while reducing overall net costs from the NHS perspective in England.Trial RegistrationClinicalTrials.gov identifier, NCT02065791.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Dialysis | Endocrinology | Heart | Heart Attack | Heart Failure | Heart Transplant | Invokana | Kidney Transplant | Kidney Transplantation | Stroke | Study | Transplant Surgery | Transplants | Urology & Nephrology